|
Areas of Practice For more than 20 years, Joel has advised companies in the healthcare, medical device, pharmaceutical and biotech industries. His clients include pharmaceutical, medical device and biotech manufacturers; managed care and pharmacy-benefit management companies; physician practices; physician-practice management firms; companies developing clinics in retail settings; and companies engaged in the development and management of ancillary-services facilities. Joel assists clients in evaluating strategic relationships and transactions as they relate to clients� business goals and objectives, and then structures and negotiates transactions suited to the companies� objectives. He also advises companies on compliance, pricing, advertising and promotion considerations relative to healthcare laws and regulations, including federal fraud-and-abuse and Stark laws and regulations. A client interviewed by Chambers & Partners for the 2007 edition of America�s Leading Lawyers for Business praises Joel�s good mix of legal and business sense he takes your business objectives and formats them into a legal framework. Representative Experience Negotiated the in-licensing for the domestic development, regulatory approval and commercialization of a drug developed abroad. For a healthcare company, negotiated the acquisition of a business to serve as the platform for a product line in a new business sector. Negotiated the NIH license for a biologic product developed under a cooperative research and development arrangement with the NIH. Negotiated an arrangement with a vaccine manufacturer in central Europe for the joint development and contract manufacture and supply of vaccine developed in the U.S. Prepared contract documentation for a drug innovator to use for its clinical studies required to support regulatory approval. Negotiated and documented a pharmaceutical company�s engagement of a contract research organization (CRO). Joel lectures frequently on industry topics related to strategic transactions including mergers and acquisitions, licensing, and strategic business planning. He is also a contributing author of A Guide to Biotechnology Finance (2005).
| 